Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma.
Between July 2003 and March 2004, nine patients with pretreated mycosis fungoides were enrolled into a phase II trial and were treated with temozolomide. The overall response rate was 33%. Further studies are needed to test the efficacy of temozolomide, alone or in combination in earlier stages of this disease.
Tani
Monica
M
Fina
Mariapaola
M
Alinari
Lapo
L
Stefoni
Vittorio
V
Baccarani
Michele
M
Zinzani
Pier Luigi
PL
D000368:Aged; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy* / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000453:epidemiology; D000077204:Temozolomide
D003606:Dacarbazine; D000077204:Temozolomide